We are proud to showcase the first three review articles published by members of the eRaDicate consortium.
- Hantusch B*, Kenner L*, Stanulović VS, Hoogenkamp M*, Brown G*. Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer. International Journal of Molecular Sciences. 2024; 25(17):9245. https://doi.org/10.3390/ijms25179245
* eRaDicate members
In this article, we bring to attention that there is extensive crosstalk and cooperation between the actions of various steroid hormone and vitamin nuclear receptors. Our program will look at whether there is a therapeutic benefit to co-targeting nuclear receptors as opposed to targeting just a single receptor.
- Powała A, Żołek T*, Brown G*, Kutner A*. Structure and the Anticancer Activity of Vitamin D Receptor Agonists. International Journal of Molecular Sciences. 2024; 25(12):6624. https://doi.org/10.3390/ijms25126624
* eRaDicate members
In this article, we examined how the anticancer activity of vitamin D agonists relates to their structure. This is important to the selection of a potent analogue for potential use in differentiation therapy.
- Powała K, Żołek T*, Brown G*, Kutner A*. Molecular Interactions of Selective Agonists and Antagonists with the Retinoic Acid Receptor γ. International Journal of Molecular Sciences. 2024; 25(12):6568. https://doi.org/10.3390/ijms25126568
* eRaDicate members
In this article, we modelled how synthetic agonists and antagonists bind to the retinoic acid receptor g. This is important to an aim of our program, i.e. to synthesise a hybrid compound that combines the RARg antagonist’s anti-cancer stem cell action with the differentiating action of a selected potent vitamin D analogue.